Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

John Moore Biography and Net Worth

General Counsel of Edgewise Therapeutics

John Moore has served as our General Counsel since September 2020. He has many years of experience as General Counsel for small molecule biopharmaceutical companies working in a range of therapeutic areas. Mr. Moore was most recently General Counsel and Secretary at Peloton Therapeutics, where he led the legal aspects of the company’s initial public offering efforts and advised on its acquisition by Merck on the eve of its planned IPO. Prior to Peloton, Mr. Moore served for 15 years as General Counsel and Secretary at Array BioPharma, Inc. and for 5 years on the board of directors of Nivalis Therapeutics. Prior to Array, he was an attorney in private practice with Wilson Sonsini. Mr. Moore holds a B.S. in chemistry from the University of North Carolina, an M.S. in biochemistry from the University of Illinois and a J.D. from the University of North Carolina.

What is John R. Moore's net worth?: The estimated net worth of John R. Moore is at least $103,901.40 as of September 20th, 2024. Mr. Moore owns 3,252 shares of Edgewise Therapeutics stock worth more than $103,901 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Moore may own. Learn More about John R. Moore's net worth.
How old is John R. Moore?: Mr. Moore is currently 60 years old. There are 8 older executives and no younger executives at Edgewise Therapeutics. The oldest executive at Edgewise Therapeutics is Dr. Joanne M. Donovan M.D., Ph.D., Chief Medical Officer, who is 67 years old. Learn More on John R. Moore's age.
How do I contact John R. Moore?: The corporate mailing address for Mr. Moore and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on John R. Moore's contact information.
Has John R. Moore been buying or selling shares of Edgewise Therapeutics?: John R. Moore has not been actively trading shares of Edgewise Therapeutics over the course of the past ninety days. Learn More on John R. Moore's trading history.
Who are Edgewise Therapeutics' active insiders?: Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.
Are insiders buying or selling shares of Edgewise Therapeutics?: During the last twelve months, Edgewise Therapeutics insiders bought shares 2 times. They purchased a total of 465,402 shares worth more than $5,100,965.10. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 592,545 shares worth more than $11,865,014.27. The most recent insider tranaction occured on September, 23rd when General Counsel John R Moore sold 20,922 shares worth more than $578,074.86. Insiders at Edgewise Therapeutics own 24.1% of the company. Learn More about insider trades at Edgewise Therapeutics.
Information on this page was last updated on 9/23/2024.

John R. Moore Insider Trading History at Edgewise Therapeutics

John R. Moore Buying and Selling Activity at Edgewise Therapeutics

Edgewise Therapeutics Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Today's Range

Now: $32.24

$31.71

$32.80

50 Day Range

MA: $30.37

$16.86

$36.62

2 Week Range

Now: $32.24

$5.93

$38.12

Volume

62,343 shs

Average Volume

944,373 shs

Market Capitalization

$3.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Claim your FREE 2024 Gold Guide

John Moore Biography and Net Worth

What is John R. Moore's net worth?

How old is John R. Moore?

How do I contact John R. Moore?

Has John R. Moore been buying or selling shares of Edgewise Therapeutics?

Who are Edgewise Therapeutics' active insiders?

Are insiders buying or selling shares of Edgewise Therapeutics?